Vasculogenic mimicry in small cell lung cancer

Nature Communications

Volumn 7, Issue , 2016, Pages

  Williamson, Stuart C ^a   Metcalf, Robert L ^a   Trapani, Francesca ^a   Mohan, Sumitra ^a   Antonello, Jenny ^a   Abbott, Benjamin ^a   Leong, Hui Sun ^a   Chester, Christopher P E ^a   Simms, Nicole ^a   Polanski, Radoslaw ^a   Nonaka, Daisuke ^b   Priest, Lynsey ^a   Fusi, Alberto ^b   Carlsson, Fredrika ^c   Carlsson, Anders ^c   Hendrix, Mary J C ^d   Seftor, Richard E B ^d   Seftor, Elisabeth A ^d   Rothwell, Dominic G ^a   Hughes, Andrew ^e   Hicks, James ^c   Miller, Crispin ^a   Kuhn, Peter ^c   Brady, Ged ^a   Simpson, Kathryn L ^a   Blackhall, Fiona H ^a,b,e   Dive, Caroline ^a   more..

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; PROTEIN P53; VASCULAR ENDOTHELIAL CADHERIN; CADHERIN; KERATIN; LEUKOCYTE ANTIGEN; TP53 PROTEIN, HUMAN;

CANCER; CELLS AND CELL COMPONENTS; MIMICRY; MOLECULAR ANALYSIS; MUTATION; SURVIVAL; TUMOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOPSY; CANCER PROGNOSIS; CHEMOSENSITIVITY; CHROMOSOME 17P; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DRUG EFFICACY; ESOPHAGUS CANCER; FEMALE; GENE SILENCING; GENETICS; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NEXT GENERATION SEQUENCING; NONHUMAN; OVERALL SURVIVAL; PHENOTYPE; PROTEIN EXPRESSION; SMALL CELL LUNG CANCER; TISSUE MICROARRAY; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; COHORT ANALYSIS; COPY NUMBER VARIATION; DRUG SCREENING; LUNG; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SINGLE CELL ANALYSIS; TUMOR CELL LINE; TUMOR EMBOLISM; VASCULARIZATION;

ANIMALS; ANTIGENS, CD; BIOPSY; CADHERINS; CELL LINE, TUMOR; COHORT STUDIES; DNA COPY NUMBER VARIATIONS; FEMALE; HUMANS; KERATINS; LUNG; LUNG NEOPLASMS; MALE; MICE; MIDDLE AGED; MUTATION; NEOPLASTIC CELLS, CIRCULATING; NEOVASCULARIZATION, PATHOLOGIC; SINGLE-CELL ANALYSIS; SMALL CELL LUNG CARCINOMA; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84994504767     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms13322     Document Type: Article

References (64)

1. Herbst, R. S., Heymach, J. V. & Lippman, S. M. Lung cancer. N. Engl. J. Med. 359, 1367-1380 (2008).
2. Travis, W. D., Travis, L. B. & Devesa, S. S. Lung cancer. Cancer 75, 191-202 (1995).
3. Pelayo Alvarez, M., Gallego Rubio, O., Bonfill Cosp, X. & Agra Varela, Y. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev. 2009, CD001990, doi:10.1002/14651858.CD001990.pub2 (2009).
4. Morabito, A. et al. Treatment of small cell lung cancer. Crit. Rev. Oncol. Hematol. 91, 257-270 (2014).
5. Chute, J. P., Chen, T., Feigal, E., Simon, R. & Johnson, B. E. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J. Clin. Oncol. 17, 1794-1801 (1999).
6. Jahchan, N. S. et al. Identification and targeting of long-term tumorpropagating cells in small cell lung cancer. Cell Rep. 16, 644-656 (2016).
7. Maniotis, A. J. et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 155, 739-752 (1999).
8. Kirschmann, D. A., Seftor, E. A., Hardy, K. M., Seftor, R. E. & Hendrix, M. J. Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin. Cancer Res. 18, 2726-2732 (2012).
9. Seftor, R. E. et al. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res. 61, 6322-6327 (2001).
10. Itzhaki, O. et al. Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanoma. PLoS ONE 8, e57160 (2013).
11. Cao, Z. et al. Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. Eur. J. Cancer. 49, 3914-3923 (2013).
12. Wagenblast, E. et al. A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature 520, 358-362 (2015).
13. Bittner, M. et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536-540 (2000).
14. Seftor, E. A. et al. Molecular determinants of human uveal melanoma invasion and metastasis. Clin. Exp. Metastasis. 19, 233-246 (2002).
15. Seftor, E. A. et al. Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasculogenic mimicry. Crit. Rev. Oncol. Hematol. 44, 17-27 (2002).
16. Hendrix, M. J., Seftor, E. A., Hess, A. R. & Seftor, R. E. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat. Rev. Cancer 3, 411-421 (2003).
17. Paulis, Y. W. et al. CD44 enhances tumor aggressiveness by promoting tumor cell plasticity. Oncotarget 6, 19634-19646 (2015).
18. Liu, T. et al. USP44+ cancer stem cell subclones contribute to breast cancer aggressiveness by promoting vasculogenic mimicry. Mol. Cancer Ther. 14, 2121-2131 (2015).
19. Cui, Y. F. et al. Claudin-4 is required for vasculogenic mimicry formation in human breast cancer cells. Oncotarget 6, 11087-11097 (2015).
20. Hendrix, M. J. et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc. Natl Acad. Sci. USA 98, 8018-8023 (2001).
21. Lezcano, C. et al. Merkel cell carcinoma expresses vasculogenic mimicry: demonstration in patients and experimental manipulation in xenografts. Lab. Invest. 94, 1092-1102 (2014).
22. Hou, J. M. et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J. Clin. Oncol. 30, 525-532 (2012).
23. Hodgkinson, C. L. et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat. Med. 20, 897-903 (2014).
24. Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307 (2011).
25. Seftor, R. E. et al. Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am. J. Pathol. 181, 1115-1125 (2012).
26. Leslie, M. Tumors' do-it-yourself blood vessels. Science 352, 1381-1383 eng (2016).
27. Hosokawa, M. et al. Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system. PLoS ONE 8, e67466 (2013).
28. Travis, W. D., Brambilla, E., Burke, A. P., Marx, A. & Nicholson, A. G. (eds) World Health Organization Classification of Tumours of the Lung, Pleura, Thymus and Heart (International Agency for Research on Cancer, 2015).
29. George, J. et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524, 47-53 (2015).
30. Staaf, J. et al. Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma. Int. J. Cancer 132, 2020-2031 (2013).
31. Chudziak, J. et al. Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer. Analyst 141, 669-678 (2016).
32. Rothwell, D. G. et al. Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample. Mol. Oncol. 10, 566-574 (2016).
33. Girotti, M. R. et al. Application of sequencing, liquid biopsies, and patientderived xenografts for personalized medicine in melanoma. Cancer Discov. 6, 286-299 (2016).
34. Tang, N. N. et al. HIF-1alpha induces VE-cadherin expression and modulates vasculogenic mimicry in esophageal carcinoma cells. World J. Gastroenterol. 20, 17894-17904 (2014).
35. Mao, X. G. et al. CDH5 is specifically activated in glioblastoma stemlike cells and contributes to vasculogenic mimicry induced by hypoxia. Neuro. Oncol. 15, 865-879 (2013).
36. Hendrix, M. J. et al. Tumor cell vascular mimicry: novel targeting opportunity in melanoma. Pharmacol. Ther. 159, 83-92 (2016).
37. Hendrix, M. J., Seftor, E. A., Hess, A. R. & Seftor, R. E. Molecular plasticity of human melanoma cells. Oncogene 22, 3070-3075 (2003).
38. Auperin, A. et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N. Engl. J. Med. 341, 476-484 (1999).
39. Janne, P. A. et al. Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer 95, 1528-1538 (2002).
40. Howlader, N. et al. SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD, based on November 2014 SEER data submission, posted to the SEER web site, 2015. Available from: http://seer.cancer.gov/csr/1975-2012/2015. Accessed November 2015.
41. Vincent, L. et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelialcadherin signaling. J. Clin. Invest. 115, 2992-3006 (2005).
42. Khalfaoui-Bendriss, G. et al. Adrenomedullin blockade induces regression of tumor neovessels through interference with vascular endothelial-cadherin signalling. Oncotarget 6, 7536-7553 (2015).
43. Krop, I. et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J. Clin. Oncol. 30, 2307-2313 (2012).
44. Schott, A. F. et al. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin. Cancer Res. 19, 1512-1524 (2013).
45. Fouladi, M. et al. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J. Clin. Oncol. 29, 3529-3534 (2011).
46. Clevers, H. The cancer stem cell: premises, promises and challenges. Nat. Med. 17, 313-319 (2011).
47. Kreso, A. & Dick, J. E. Evolution of the cancer stem cell model. Cell. Stem. Cell. 14, 275-291 (2014).
48. Polanski, R. et al. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin. Cancer Res. 20, 926-937 (2014).
49. Vona, G. et al. Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. Hepatology 39, 792-797 (2004).
50. Smith, N. R. et al. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin. Cancer Res. 16, 3548-3561 (2010).
51. Liedert, B., Pluim, D., Schellens, J. & Thomale, J. Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res. 34, e47 (2006).
52. Potter, D. S. et al. Inhibition of PI3K/BMX cell survival pathway sensitizes to BH3 mimetics in SCLC. Mol. Cancer Ther. 15, 1248-1260 (2016).
53. Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26, 589-595 (2010).
54. Ha, G. et al. Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer. Genome Res. 22, 1995-2007 (2012).
55. Lai, D. & Shah, S. HMMcopy: copy number prediction with correction for GC and mappability bias for HTS data. R package version 1.10.0. (2012).
56. Li, H. et al. The Sequence Alignment/Map format and SAM tools. Bioinformatics 25, 2078-2079 (2009).
57. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).
58. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013).
59. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).
60. Dago, A. E. et al. Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells. PLoS ONE 9, e101777 (2014).
61. Baslan, T. et al. Genome-wide copy number analysis of single cells. Nat. Protoc. 7, 1024-1041 (2012).
62. Baslan, T. et al. Optimizing sparse sequencing of single cells for highly multiplex copy number profiling. Genome Res. 25, 714-724 (2015).
63. Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90-94 (2011).
64. Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 8, e1000412 (2010).